Cheng L, Montironi R, Bostwick DG, Lopez‐Beltran A & Berney DM (2012) Histopathology
60, 87–117 Staging of prostate cancer Prostatic carcinoma (PCa) is a significant cause of …

Context Optimal management of prostate cancer (PCa) patients with lymph node invasion at
radical prostatectomy and pelvic lymph node dissection still remains unclear. Objective To …

Distinguishing aggressive prostate cancer from indolent disease represents an important
clinical challenge, because current therapy may lead to overtreatment of men with limited …

Oncosomes have recently been described as membrane-derived microvesicles secreted by
cancer cells, which transfer oncogenic signals and protein complexes across cell …

Prostate cancer is a common and clinically heterogeneous disease with marked variability in
progression. The recent identification of gene fusions of the 5′-untranslated region of …

Prostate cancer (PCA) is one of the most prevalent cancers and a major leading cause of
morbidity and mortality in the Western world. The TMPRSS2-ERG fusion was recently …

Mutations in the androgen receptor (AR) that enable activation by antiandrogens occur in
hormone-refractory prostate cancer, suggesting that mutant ARs are selected by treatment …

Recent studies have established that a significant fraction of prostate cancers harbor a
signature gene fusion between the 5'region of androgen-regulated TMPRSS2 and an ETS …

Localized prostate cancer (CaP) can be cured using several strategies. However, the need
to identify active substances in advanced tumor stages is tremendous, as the outcome in …

Objectives To investigate whether patients with suspected pelvic lymph node metastases
(molecular imaging [mi] N1) on staging prostate‐specific membrane antigen (PSMA) …